Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Gross Margin (2018 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Gross Margin for 8 consecutive years, with 85.84% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 373.0% to 85.84% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 83.8% through Dec 2025, down 245.0% year-over-year, with the annual reading at 83.8% for FY2025, 245.0% down from the prior year.
  • Gross Margin for Q4 2025 was 85.84% at Ultragenyx Pharmaceutical, up from 82.5% in the prior quarter.
  • The five-year high for Gross Margin was 96.39% in Q2 2021, with the low at 79.42% in Q1 2025.
  • Average Gross Margin over 5 years is 89.32%, with a median of 90.03% recorded in 2022.
  • The sharpest move saw Gross Margin soared 443bps in 2021, then tumbled -565bps in 2022.
  • Over 5 years, Gross Margin stood at 95.79% in 2021, then decreased by -1bps to 94.85% in 2022, then decreased by -4bps to 90.69% in 2023, then decreased by -1bps to 89.57% in 2024, then decreased by -4bps to 85.84% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 85.84%, 82.5%, and 86.18% for Q4 2025, Q3 2025, and Q2 2025 respectively.